friulimicin B

Friulimicin B is a naturally occurring cyclic lipopeptide antibiotic produced by the actinomycete Actinoplanes friuliensis. It exhibits potent bactericidal activity against a broad spectrum of gram-positive pathogens, including multidrug-resistant strains such as methicillin-resistant Staphylococcus aureus and enterococci. Structurally, it consists of a macrocyclic decapeptide core with an exocyclic asparagine linked to a branched-chain fatty acid tail. Friulimicin B is water-soluble and amphiphilic, with its antimicrobial activity being calcium-dependent. The mechanism of action for friulimicin B is unique among antibiotics; it interrupts the cell wall precursor cycle by forming a calcium-dependent complex with the bactoprenol phosphate carrier (C55-P), which is essential for peptidoglycan and teichoic acid biosynthesis in gram-positive bacteria. This disrupts multiple pathways critical for maintaining the bacterial cell envelope integrity[1][5][7][8]. Friulimicin B was developed primarily for hospital-acquired (nosocomial) infections but has not advanced beyond early clinical development[3][4].

Other names

friulimicinfriulimycin B